logo

AARTIPHARM vs GRANULES: Stock Comparison

AARTI PHARMALABS vs GRANULES INDIAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. AARTI PHARMALABS shows a higher ROE and a higher dividend yield, while GRANULES INDIA shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIPHARM leads 4; GRANULES leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIPHARMGRANULES

Valuation lens

What price are you paying?

Market CapContext only
₹7,538 Cr
₹22,358 Cr
P/E RatioGRANULES has the lower reading
35.25x
30.39x ✓
P/B RatioAARTIPHARM has the lower reading
3.55x ✓
3.99x
EPSAARTIPHARM has the higher reading
₹23.5 ✓
₹7.26
Book ValueContext only
₹234.28
₹205.21
Dividend YieldAARTIPHARM has the higher reading
0.48% ✓
0.22%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹22,358 Cr vs ₹7,538 Cr
P/E Ratio
GRANULES has a lower P/E
30.39x vs 35.25x
P/B Ratio
AARTIPHARM has a lower P/B
3.55x vs 3.99x
EPS
AARTIPHARM has higher earnings per share
₹23.5 vs ₹7.26
Dividend Yield
AARTIPHARM has a higher dividend yield
0.48% vs 0.22%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 3.3%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs -30.8%
ROE
AARTIPHARM has a higher ROE
9.48% vs 9.11%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIPHARMGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIPHARMGRANULES
Live Price₹828.8₹817
Day Change-1.71%1.16%
Volume4.15 L5.12 L
52-Week High₹1,002.4₹923.65
52-Week Low₹585₹529.85
Distance from 52W High-17.32%-11.55%

Valuation

MetricAARTIPHARMGRANULES
Market Cap₹7,538 Cr₹22,358 Cr
P/E Ratio35.25x30.39x
P/B Ratio3.55x3.99x
EPS₹23.5₹7.26
Book Value₹234.28₹205.21
Dividend Yield0.48%0.22%

Growth

MetricAARTIPHARMGRANULES
Revenue Growth (TTM YoY)3.3%22.8%
EPS Growth (TTM YoY)-30.8%31.3%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricAARTIPHARMGRANULES
ROE9.48%9.11%
ROCE8.38%9.07%
Net Margin10.25%11.15%
Operating Margin16.52%17.19%
Debt to Equity0.35x0.17x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAARTIPHARMGRANULES
Promoter Holding39.49%▼ 3.2 pp37.08%▼ 0.59 pp
FII Holding8.15%▼ 0.02 pp20.25%▲ 2.75 pp
DII Holding8.4%▲ 1.18 pp15.33%▼ 0.78 pp
Public Holding43.78%▲ 2.04 pp27.04%▼ 1.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI PHARMALABS and GRANULES INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.